Population-based prevalence of cerebral cavernous malformations in older adults: Mayo clinic study of aging

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

IMPORTANCE: The prevalence of cerebral cavernous malformation (CCM) is unknown. Case ascertainment in most previous studies was based on autopsy data or clinical convenience samples, often without detailed clinical or radiologic information. OBJECTIVE: To determine the prevalence of CCM in a population-based sample of older adults. DESIGN, SETTING, AND PARTICIPANTS: This prospective imaging study included 4721 participants aged 50 to 89 years who were enrolled between January 1, 2004, and December 15, 2015, in the Mayo Clinic Study of Aging, a longitudinal, population-based study of residents of Olmsted County, Minnesota. An age- and sex-stratified sampling strategy was used to randomly select participants from Olmsted County using the medical records linkage system of the Rochester Epidemiology Project. Participants were invited to undergo brain magnetic resonance imaging (MRI). Of the 4721 participants, 2715 had an evaluable MRI. All images were reviewed by a board-certified neuroradiologist, and MRI reports were searched for the terms cavernous malformation, cavernous angioma, and cavernoma. Two vascular neurologists reviewed MRIs, and potential CCMs were classified using Zabramski classification. Medical records of the identified individuals with CCM were reviewed along with their demographic information, medical history, and any symptoms referable to the identified CCM lesion. MAIN OUTCOMES AND MEASURES: Prevalence of CCM and clinical and radiologic characteristics of study participants with CCM. RESULTS Of the 2715 participants who underwent MRI scans, 12 (0.44%) had CCM. With the use of inverse probability weights to adjust for participation bias, the overall prevalence was 0.46%(95%CI, 0.05-0.86). The age-adjusted prevalence was found to be 0.61% (95%CI, 0-1.47) for the 50- to 59-year age group, 0.17%(95%CI, 0-0.50) for the 60- to 69-year age group, 0.45%(95%CI, 0.09-0.81) for the 70- to 79-year age group, and 0.58%(95%CI, 0-1.29) for the 80- to 89-year age group. The sex-adjusted prevalence was 0.41% (95%CI, 0-1.00) for women and 0.51%(95%CI, 0-1.07) for men. Observed frequencies were similar in men and women, with a slight male predominance. Of the 12 participants with CCM, 9 (75%) had a single Zabramski type 2 lesion in a supratentorial location. Only 1 participant (0.037%) was symptomatic from the CCM during the study period. CONCLUSIONS AND RELEVANCE: The findings and data from this study are important for determining the potential number of patients available for cohort studies and anticipated clinical trials in older patients with CCM.

Original languageEnglish (US)
Pages (from-to)801-805
Number of pages5
JournalJAMA Neurology
Volume74
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Central Nervous System Cavernous Hemangioma
Population
Age Groups
Magnetic Resonance Imaging
Medical Record Linkage
Cavernous Hemangioma
Medical Records
Blood Vessels
Autopsy
Epidemiology
Cohort Studies

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

@article{351a3d7475c84c1287cb20c87e16f55b,
title = "Population-based prevalence of cerebral cavernous malformations in older adults: Mayo clinic study of aging",
abstract = "IMPORTANCE: The prevalence of cerebral cavernous malformation (CCM) is unknown. Case ascertainment in most previous studies was based on autopsy data or clinical convenience samples, often without detailed clinical or radiologic information. OBJECTIVE: To determine the prevalence of CCM in a population-based sample of older adults. DESIGN, SETTING, AND PARTICIPANTS: This prospective imaging study included 4721 participants aged 50 to 89 years who were enrolled between January 1, 2004, and December 15, 2015, in the Mayo Clinic Study of Aging, a longitudinal, population-based study of residents of Olmsted County, Minnesota. An age- and sex-stratified sampling strategy was used to randomly select participants from Olmsted County using the medical records linkage system of the Rochester Epidemiology Project. Participants were invited to undergo brain magnetic resonance imaging (MRI). Of the 4721 participants, 2715 had an evaluable MRI. All images were reviewed by a board-certified neuroradiologist, and MRI reports were searched for the terms cavernous malformation, cavernous angioma, and cavernoma. Two vascular neurologists reviewed MRIs, and potential CCMs were classified using Zabramski classification. Medical records of the identified individuals with CCM were reviewed along with their demographic information, medical history, and any symptoms referable to the identified CCM lesion. MAIN OUTCOMES AND MEASURES: Prevalence of CCM and clinical and radiologic characteristics of study participants with CCM. RESULTS Of the 2715 participants who underwent MRI scans, 12 (0.44{\%}) had CCM. With the use of inverse probability weights to adjust for participation bias, the overall prevalence was 0.46{\%}(95{\%}CI, 0.05-0.86). The age-adjusted prevalence was found to be 0.61{\%} (95{\%}CI, 0-1.47) for the 50- to 59-year age group, 0.17{\%}(95{\%}CI, 0-0.50) for the 60- to 69-year age group, 0.45{\%}(95{\%}CI, 0.09-0.81) for the 70- to 79-year age group, and 0.58{\%}(95{\%}CI, 0-1.29) for the 80- to 89-year age group. The sex-adjusted prevalence was 0.41{\%} (95{\%}CI, 0-1.00) for women and 0.51{\%}(95{\%}CI, 0-1.07) for men. Observed frequencies were similar in men and women, with a slight male predominance. Of the 12 participants with CCM, 9 (75{\%}) had a single Zabramski type 2 lesion in a supratentorial location. Only 1 participant (0.037{\%}) was symptomatic from the CCM during the study period. CONCLUSIONS AND RELEVANCE: The findings and data from this study are important for determining the potential number of patients available for cohort studies and anticipated clinical trials in older patients with CCM.",
author = "Kelly Flemming and Jonathan Graff-Radford and Jeremiah Aakre and Kantarci, {Kejal M} and Giuseppe Lanzino and Brown, {Robert D Jr.} and Mielke, {Michelle M} and Roberts, {Rosebud O} and Kremers, {Walter K} and Knopman, {David S} and Petersen, {Ronald Carl} and Jack, {Clifford R Jr.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1001/jamaneurol.2017.0439",
language = "English (US)",
volume = "74",
pages = "801--805",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Population-based prevalence of cerebral cavernous malformations in older adults

T2 - Mayo clinic study of aging

AU - Flemming, Kelly

AU - Graff-Radford, Jonathan

AU - Aakre, Jeremiah

AU - Kantarci, Kejal M

AU - Lanzino, Giuseppe

AU - Brown, Robert D Jr.

AU - Mielke, Michelle M

AU - Roberts, Rosebud O

AU - Kremers, Walter K

AU - Knopman, David S

AU - Petersen, Ronald Carl

AU - Jack, Clifford R Jr.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - IMPORTANCE: The prevalence of cerebral cavernous malformation (CCM) is unknown. Case ascertainment in most previous studies was based on autopsy data or clinical convenience samples, often without detailed clinical or radiologic information. OBJECTIVE: To determine the prevalence of CCM in a population-based sample of older adults. DESIGN, SETTING, AND PARTICIPANTS: This prospective imaging study included 4721 participants aged 50 to 89 years who were enrolled between January 1, 2004, and December 15, 2015, in the Mayo Clinic Study of Aging, a longitudinal, population-based study of residents of Olmsted County, Minnesota. An age- and sex-stratified sampling strategy was used to randomly select participants from Olmsted County using the medical records linkage system of the Rochester Epidemiology Project. Participants were invited to undergo brain magnetic resonance imaging (MRI). Of the 4721 participants, 2715 had an evaluable MRI. All images were reviewed by a board-certified neuroradiologist, and MRI reports were searched for the terms cavernous malformation, cavernous angioma, and cavernoma. Two vascular neurologists reviewed MRIs, and potential CCMs were classified using Zabramski classification. Medical records of the identified individuals with CCM were reviewed along with their demographic information, medical history, and any symptoms referable to the identified CCM lesion. MAIN OUTCOMES AND MEASURES: Prevalence of CCM and clinical and radiologic characteristics of study participants with CCM. RESULTS Of the 2715 participants who underwent MRI scans, 12 (0.44%) had CCM. With the use of inverse probability weights to adjust for participation bias, the overall prevalence was 0.46%(95%CI, 0.05-0.86). The age-adjusted prevalence was found to be 0.61% (95%CI, 0-1.47) for the 50- to 59-year age group, 0.17%(95%CI, 0-0.50) for the 60- to 69-year age group, 0.45%(95%CI, 0.09-0.81) for the 70- to 79-year age group, and 0.58%(95%CI, 0-1.29) for the 80- to 89-year age group. The sex-adjusted prevalence was 0.41% (95%CI, 0-1.00) for women and 0.51%(95%CI, 0-1.07) for men. Observed frequencies were similar in men and women, with a slight male predominance. Of the 12 participants with CCM, 9 (75%) had a single Zabramski type 2 lesion in a supratentorial location. Only 1 participant (0.037%) was symptomatic from the CCM during the study period. CONCLUSIONS AND RELEVANCE: The findings and data from this study are important for determining the potential number of patients available for cohort studies and anticipated clinical trials in older patients with CCM.

AB - IMPORTANCE: The prevalence of cerebral cavernous malformation (CCM) is unknown. Case ascertainment in most previous studies was based on autopsy data or clinical convenience samples, often without detailed clinical or radiologic information. OBJECTIVE: To determine the prevalence of CCM in a population-based sample of older adults. DESIGN, SETTING, AND PARTICIPANTS: This prospective imaging study included 4721 participants aged 50 to 89 years who were enrolled between January 1, 2004, and December 15, 2015, in the Mayo Clinic Study of Aging, a longitudinal, population-based study of residents of Olmsted County, Minnesota. An age- and sex-stratified sampling strategy was used to randomly select participants from Olmsted County using the medical records linkage system of the Rochester Epidemiology Project. Participants were invited to undergo brain magnetic resonance imaging (MRI). Of the 4721 participants, 2715 had an evaluable MRI. All images were reviewed by a board-certified neuroradiologist, and MRI reports were searched for the terms cavernous malformation, cavernous angioma, and cavernoma. Two vascular neurologists reviewed MRIs, and potential CCMs were classified using Zabramski classification. Medical records of the identified individuals with CCM were reviewed along with their demographic information, medical history, and any symptoms referable to the identified CCM lesion. MAIN OUTCOMES AND MEASURES: Prevalence of CCM and clinical and radiologic characteristics of study participants with CCM. RESULTS Of the 2715 participants who underwent MRI scans, 12 (0.44%) had CCM. With the use of inverse probability weights to adjust for participation bias, the overall prevalence was 0.46%(95%CI, 0.05-0.86). The age-adjusted prevalence was found to be 0.61% (95%CI, 0-1.47) for the 50- to 59-year age group, 0.17%(95%CI, 0-0.50) for the 60- to 69-year age group, 0.45%(95%CI, 0.09-0.81) for the 70- to 79-year age group, and 0.58%(95%CI, 0-1.29) for the 80- to 89-year age group. The sex-adjusted prevalence was 0.41% (95%CI, 0-1.00) for women and 0.51%(95%CI, 0-1.07) for men. Observed frequencies were similar in men and women, with a slight male predominance. Of the 12 participants with CCM, 9 (75%) had a single Zabramski type 2 lesion in a supratentorial location. Only 1 participant (0.037%) was symptomatic from the CCM during the study period. CONCLUSIONS AND RELEVANCE: The findings and data from this study are important for determining the potential number of patients available for cohort studies and anticipated clinical trials in older patients with CCM.

UR - http://www.scopus.com/inward/record.url?scp=85024393432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024393432&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2017.0439

DO - 10.1001/jamaneurol.2017.0439

M3 - Article

C2 - 28492932

AN - SCOPUS:85024393432

VL - 74

SP - 801

EP - 805

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 7

ER -